A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
Active, not recruiting · NCT05222802 · Registry updated 2025-08-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 | 2025-08-17 | NCT05222802 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Erasca, Inc. | 5 |
| Katmai Pharmaceuticals Inc. | 1 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cleveland Clinic Foundation | Cleveland | United States | 370 |
| Dana Farber Cancer Institute | Boston | United States | 300 |
| Henry Ford Health System | Detroit | United States | 147 |
| Huntsman Cancer Institute | Salt Lake City | United States | 107 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 16 |
| Miami Cancer Institute-Baptist Heath South Florida | Miami | United States | 1 |
| Sarah Cannon Research Institute (Tennessee Oncology) | Nashville | United States | 1 |
| University of California, Los Angeles | Los Angeles | United States | 142 |